Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24‐week, double‐blind, randomized trial

Aims:  The study evaluated the efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor, vildagliptin, and metformin in drug‐naïve elderly patients with type 2 diabetes. The primary objective was to demonstrate non‐inferiority of vildagliptin vs. metformin in glycated haemoglobin (HbA1c) reduction.

[1]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[2]  A. Garber,et al.  Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea * , 2008, Diabetes, obesity & metabolism.

[3]  W. Scherbaum,et al.  Efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia * , 2008, Diabetes, obesity & metabolism.

[4]  G. McMahon,et al.  Intensive glycemic control in the ACCORD and ADVANCE trials. , 2008, The New England journal of medicine.

[5]  J. Foley,et al.  Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[6]  M. Persson,et al.  Vildagliptin improves alpha cell glucose sensing in patients with type 2 diabetes , 2008 .

[7]  P. Nilsson,et al.  Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemia , 2008 .

[8]  J. Rosenstock,et al.  Management of Type 2 Diabetes in Treatment-Naive Elderly Patients , 2007, Diabetes Care.

[9]  S. Dejager,et al.  Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[10]  S. Dejager,et al.  Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. , 2007, Diabetes research and clinical practice.

[11]  J. Holst,et al.  The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. , 2007, The Journal of clinical endocrinology and metabolism.

[12]  S. Dejager,et al.  Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes , 2007, Diabetologia.

[13]  A. Garber,et al.  Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study * , 2007, Diabetes, obesity & metabolism.

[14]  S. Dejager,et al.  Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[15]  J. Rosenstock,et al.  Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes , 2007, Diabetes, obesity & metabolism.

[16]  J. Rosenstock,et al.  Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes , 2007, Diabetes Care.

[17]  M. Stumvoll,et al.  Contraindications can damage your health—is metformin a case in point? , 2005, Diabetologia.

[18]  M. Goodarzi,et al.  Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents , 2005, Diabetes, obesity & metabolism.

[19]  J. Holst,et al.  Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. , 2005, The Journal of clinical endocrinology and metabolism.

[20]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[21]  Bo Ahrén,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels , 2022 .

[22]  R. Heine,et al.  Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. , 2003, Diabetes care.

[23]  Claudio Cobelli,et al.  Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. , 2003, Diabetes.

[24]  J. Holst,et al.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. , 2002, The Journal of clinical endocrinology and metabolism.

[25]  J. Rosenstock.  Management of Type 2 Diabetes Mellitus in the Elderly , 2001, Drugs & aging.

[26]  Paolisso,et al.  Effect of metformin on food intake in obese subjects , 1998, European journal of clinical investigation.

[27]  J. Morley,et al.  Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. , 1998, Obesity research.

[28]  A. Garber,et al.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. , 1997, The American journal of medicine.

[29]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.